Recruiting

Immunotherapy Protocols

Sponsor:

National Cancer Institute (NCI)

Code:

NCT02682667

Conditions

Multiple Myeloma

Lymphoma, Non-Hodgkin

Leukemia-Lymphoma, Adult T-Cell

Hodgkin Disease

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Background:

Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.

Objective:

To better understand the biology of malignancies and why certain cancers respond differently to treatment.

Eligibility:

Adults at least 18 years old with cancer or a pre-cancerous condition.

Design:

Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.

Participants will send tissue blocks or slides from their original tumor biopsy.

At least once, participants will have a medical history, physical exam, and blood and urine tests.

Participants may have the following tests. They may have them more than once:

Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.

Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.

Piece of cancer tissue taken by a needle and syringe.

Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.

A small piece of skin removed.

Participants will be contacted by phone once a year to find out how they are doing.

Conditions

Multiple Myeloma

Lymphoma, Non-Hodgkin

Leukemia-Lymphoma, Adult T-Cell

Hodgkin Disease

Non-Small Cell Lung Cancer

Study ID

NCT02682667

Start date

Apr 11, 2016

Status verified date

Jun 17, 2026

Completion date

Dec 1, 2032

Anticipated

Primary completion date

Dec 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

  • INCLUSION CRITERIA:

1. Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition
2. Age >=18 years of age
3. ECOG performance status of 0-3.

5\. Ability and willingness of subject to provide informed consent

Additional inclusion criteria pertinent only for participants undergoing apheresis

1. Hemoglobin >= 8 mg/dL and platelet count > 75 K/microL
2. Weight >= 48 kg
3. Central line in place or adequate venous access

EXCLUSION CRITERIA:

1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.
2. Inability to provide informed consent
3. Pregnant or breastfeeding women

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

1/Cohort 1

Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency

Primary outcome measure

  • Sample Acquisition [ Time Frame: Ongoing ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Sep 1, 2026

Last verified

Jun 17, 2026

Keywords

  • Apheresis Products
  • Immunological
  • Diverse Malignan
  • Premalignant
  • Protein
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-09-01.